Big Rock Partners Acquisition Aktie [WKN DE: A3CQ3Q / ISIN: US6294441000]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Big Rock Partners Acquisition Corp Registered Shs

10.05.23		NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call (PR Newswire)
27.04.23		NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (PR Newswire)
30.03.23		NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
27.03.23		NRx Pharma: DSMB Advises To Continue Ongoing Trial Of NRX-101 (RTTNews)
27.03.23		NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression (PR Newswire)
17.03.23		NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 (PR Newswire)
09.03.23		NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering (PR Newswire)
22.02.23		NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio (PR Newswire)
13.02.23		NRx Updates FDA Meeting On NRX-101 Development To Treat Bipolar Depression With Suicidality (RTTNews)
13.02.23		NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality (PR Newswire)
02.02.23		NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior (PR Newswire)
19.01.23		NRx Pharma Updates On Interactions With FDA Regarding Path To NDA Submission For NRX-101 (RTTNews)
19.01.23		NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101 (PR Newswire)
05.01.23		NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference (PR Newswire)
03.01.23		NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted (PR Newswire)
20.12.22		Relief, NeuroRx End Litigation; NeuroRx Transfers To Relief Formulation Of Aviptadil Product (RTTNews)
20.12.22		Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements (PR Newswire)
05.12.22		NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs (PR Newswire)
02.12.22		NRx Receives Nasdaq Notice of Listing Compliance (PR Newswire)
14.11.22		NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
14.11.22		NRx Pharma To Transfer Aviptadil Development Program Assets To Relief Therapeutics (RTTNews)
14.11.22		Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements (PR Newswire)
10.11.22		NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022 (PR Newswire)
09.11.22		NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process (PR Newswire)
07.11.22		NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing (PR Newswire)
08.09.22		NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference (PR Newswire)
15.08.22		NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise (PR Newswire)
10.08.22		NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022 (PR Newswire)
13.07.22		NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director (PR Newswire)
01.07.22		NRx Pharma: FDA Declines To Issue Emergency Use Authorization For ZYESAMI (RTTNews)
23.06.22		NRx Pharma Says Class Action Suit Against Company Dismissed (RTTNews)
11.06.22		NRx Pharma : FDA Denies Breakthrough Therapy Designation Request For Zyesami (RTTNews)
08.06.22		NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer (PR Newswire)
26.05.22		NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19 (PR Newswire)
19.05.22		NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference (PR Newswire)
16.05.22		NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results (PR Newswire)
12.05.22		NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality (PR Newswire)
10.05.22		NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022 (PR Newswire)
21.04.22		NRx Pharma Files New Breakthrough Therapy Designation Request For ZYESAMI (RTTNews)
21.04.22		NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with ... (PR Newswire)
08.04.22		NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference (PR Newswire)
31.03.22		I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill P... (PR Newswire)
31.03.22		NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results (PR Newswire)
28.03.22		NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022 (PR Newswire)
18.03.22		NRx Names Ira Strassberg As CFO (RTTNews)
12.03.22		ROSEN, A TOP RANKED FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses Over $100K to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW (PR Newswire)
09.03.22		NRx Pharmaceuticals Announces Leadership Transition (PR Newswire)
05.03.22		ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP; NRXPW (PR Newswire)
18.02.22		Pre-market Movers: NRGV, ROKU, RDFN, CELZ, SHAK… (RTTNews)
15.02.22		NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

EU-Abgeordnete fordert Bitcoin statt digitalem Euro - strategische Bitcoin-Reserve für die EU

Diese Aktien empfehlen Experten zu kaufen

APA - N A C H R I C H T E N Ü B E R B L I C K

Fed-Gouverneurin Lisa Cook und Experten sprechen klare Warnung über mögliche Korrekturen 2025 aus

Steinmeier setzt Neuwahlen für 23. Februar an

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.01.2025 20:33
Kaufwert:	EUR
	Hinzufügen Speichern